Abstract. Rabbit antithrombin III (AT), purified by heparin-agarose, was labeled with iodine-131 by either the glucose oxidase-lactoperoxidase or iodine monochloride techniques. When intravenously injected, the disappearance of the '3'I-AT from plasma was characterized by rapid initial decreases, and three-exponential equations were required for best fit of the plasma disappearance curves. This rapid '3'I-AT removal was not caused by denaturation, as shown by comparison with results obtained when '3'I-AT was biologically screened (injected into a first rabbit, and then transferred 16 h later in whole plasma to a second for kinetic evaluation) before injection. Thus, the same rapid initial loss ofplasma '3'I-AT was observed with screened preparations, and the plasma fractional catabolic rates of 0.716±0.048 and 0.673±0.051 day-' for unscreened and screened '3'I-AT were not significantly different. These results support the hypothesis that a vascular-endothelial AT compartment is present in rabbit. The fractions of the total-body AT in the plasma, the vascular-endothelial and the extravascular compartments were 0.337±0.031, 0.178+0.056, and 0.485±0.069, respectively.
Introduction
Antithrombin III (AT)' has been shown to inactivate thrombin (1), Factor Xa (2), Factor IXa (3), and the other coagulation enzymes in vitro. The high incidence of venous thrombosis among individuals with a hereditary deficiency in AT (4) , and the finding of increased levels of AT-protease complexes in the circulation of individuals with disseminated intravascular-coagulation (5) demonstrate that AT is an important inhibitor of coagulation enzymes in vivo.
The in vitro rates of the AT-protease reactions are greatly enhanced by the presence of heparin (6) . Enhancement of the AT-thrombin reaction rate also occurs in vivo (7) , and apparently in the absence of circulating heparin (8) . This effect may be mediated by a heparinlike AT cofactor that has been found on the surface of endothelial cells (9) . If this AT cofactor is present on the endothelium in vivo, it would be expected to bind some of the plasma AT with which it is in contact because of its heparinlike character.
In this investigation we studied the distribution and catabolism on AT in the intact rabbit using '31I-AT. Applying in vivo kinetic methods developed to characterize the behavior of other plasma proteins (10, 11, 12, 13) , we attempted to distinguish AT free in the circulation from that bound to the endothelium. Mathematical analysis of '3'I-AT kinetic data permitted calculation of the fractional AT distribution, as well as its catabolic rates. These results establish the rabbit as a model for study of AT in vivo.
Methods
Materials. Tosyl-glycyl-prolyl-argine-p-nitroanilide acetate (Chromozym TH) was obtained from Boehringer Mannheim Biochemicals, Indianapolis, IN. Thrombin, as a crude bovine preparation, was obtained from Parke, Davis and Co., Detroit, MI. Electrophoretic-grade acrylamide, N.N'-methylene-bisacrylamide, NN.N',N',-tetramethylenediamine, ammonium persulfate, sodium dodecylsulfate, 2-mercaptoethanol, Coomassie brilliant Blue R and Enzymobead (lactoperoxidaseglucose oxidase enzyme system immobilized on polyacrylamide beads) were from Bio-Rad Laboratories, Richmond, CA. Sepharose 4B was a product of Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, NJ. Heparin (stage 14) for heparin-agarose preparation was obtained from Inolex Corp., Chicago, IL. Heparin for heparin-cofactor assay was 5,000 U/ml from Organon, Inc., West Orange, NJ. Polybrene was from Aldrich Chemical Co., Inc., Milwaukee, WI. Tris-(hydroxymethyl)-aminomethane, was a product of Sigma Chemical Co., St. Louis, MO . Iodine-125 and iodine-131 were from ICN Chemical and Radioisotopes Div., Irvine, CA, or Amersham Corp., Arlington Heights, IL. All other chemicals were reagent grade or better. Heparin-agarose was prepared as described earlier, and contained 650 1Ag heparin per milliliter gel (14) .
Protein preparations. Rabbit AT was prepared by a modification of our previous technique (14) . Briefly, fresh citrated plasma was diluted 1:1 with 20.0 mM Tris-HCl, 10.0 mM sodium citrate, pH 7.2 (TCB), containing 0.3 M NaCi, before loading onto a heparin-agarose column. After loading, the column was washed with 5-20 vol of TCB, which contained 0.225 M NaCl, and then eluted with a 120-150-ml linear gradient from 0.225 M to 2.0 or 3.0 M NaCl. The fractions containing AT activity that eluted between -0.5 and 0.8 M NaCl were pooled, slowly diluted to 0.3 M NaCl with the TCB buffer, and then loaded on a heparin-agarose column. After washing with 5-10 vol of TCB, which contained 0.3 M NaCl, the column was eluted with 2.0 or 3.0 M NaCl. This method of preparation produced AT that was highly concentrated (1.5-4.0 mg/ml), homogeneous on SDS-polyacrylamide gel electrophoresis, and had a heparin-cofactor activity of -4.0 U/mg. Rabbits fibrinogen of >90% clottability was prepared by repeated precipitation of heparinized plasma with ammonium sulfate (15) .
Assays. AT inhibitory activity, assayed as heparin cofactor (16) , and AT antigen, assayed by rocket electroimmunoassay (17) , were as reported previously (14) . Fibrinogen clottability was determined by the methods described (15) .
Preparations of radioiodinated proteins. AT was labeled by either the Enzymobead technique or the iodine monochloride method (18) . The labeling procedure recommended by the Enzymobead manufacturer was modified in two ways: (a) a lower Enzymobead to protein ratio was used; (b) the reaction was carried out at 40C for 2 h. For labeling, 250 M1 of AT, obtained from the final purification step, was added to a mixture of 500 Ml of 0.2 M phosphate buffer (pH 7.2), an aliquot of 1.3 X 10-3 M cold sodium iodide to give an iodine to protein ratio of 0.5, one-fifth vial of Enzymobead, and a trace of iodine-131 ,MCi). The incorporation reaction was initiated by the addition of 250 Ml of2% alpha-D-glucose, which had been allowed to mutorotate overnight at room temperature. Iodine incorporation into AT ranged from 40 to 80%. After Enzymobead removal the reaction mixture was diluted with TCB, and loaded onto a 5.0-ml heparin-agarose column equilibrated with TCB containing 0.3 M NaCl. After washing to remove unbound iodine, the labeled protein was eluted with a linear NaCl gradient. The heparin-cofactor activity of the fractions eluting near the center of the peak of eluted radioactivity, measured as previously described (16) , was essentially identical to that of the starting material. These fractions were pooled for injections. lodination of rabbit fibrinogen was also labeled by the Enzymobead technique. The labeled protein was freed from unincorporated iodine (15) and the clottability of the resulting ['25I]fibrinogen was 94-96%.
Labeling of AT by the iodine monochloride method was carried out as described previously (15) , with all reactants at 4-C. The labeling efficiency was 20%. Biologically screened '31I-AT was prepared by injecting 100-150 MCi of '311-AT into 2.0-2.5-kg rabbits. Approximately 16 h later citrated blood was obtained from these animals by cardiac puncture, under anesthesia. Aliquots of the resulting plasma were injected into recipient animals as described below. Blood sampling and handling. Blood samples were collected 5-10 min after the injections, at 2.5-3.5 h, 5-6 times over the next 48 h, and daily thereafter up to 10 d. After a razornick in the left lateral ear vein, blood was collected 9:1 in 0.129 M sodium citrate. Volume of blood was determined by weight, and by assuming that the whole blood density was 1.06 mg/ml. Duplicate microhematocrits of the whole blood and anticoagulated blood were obtained.
After centrifugation for 10 min at 2,000 X g, 1 ml of plasma was aspirated for counting of radioactivity. In preliminary experiments, 1 ml of whole citrated blood was also counted to determine if any of the '311-AT became associated with the formed elements. It was found that the whole blood radioactivity was identical to the radioactivity of the plasma in the sample, within limits of experimental error. Therefore, only plasma was counted for results reported below. Plasma non-proteinbound radioactivity was determined as described previously (19) , except that 50 Ml of 2% dexoycholate per milliliter of plasma was added before TCA precipitation.
Counting was in a Packard model 5230 (Packard Instrument Co., Downers Grove, IL) or Searle model 1197 (Searle Analytic, Inc., Des Plaines, IL) dual channel crystal scintillation counters. Counting rates of samples containing both iodine-125 and iodine-131 were corrected for iodine-1 31 counts which spilled into the iodine-125 channel.
Whole-body radioactivity. Whole body radioactivity (20) was determined immediately after each blood sampling. Counting was for from 2 to 25 min.
Radioactivity data corrections and analysis. All radioactivity data was first corrected for radioactive decay and background. Correction for plasma dilution by anticoagulant (F,) was by the following formula:
(1)
where VB is the volume of blood collected, Vc is the volume of anticoagulant, and HCTB is the hematocrit/100 of the whole blood. Correction for dilution of plasma within the animal (F2) was made by application of the following formula: F2 = ( -HCTBi)/(l -HCTB'), (2) where HCTB' is the whole blood hematocrit/I00 of sample i, and HCTB' is the whole blood hematocrit of the first sample. The radioactivity removed in each blood sample was determined by multiplying the radioactivity of the 1-ml plasma sample by (1 -HCTc)VT, where HCTc is the hematocrit/100 of the anticoagulated blood sample and VT is the total volume of the sample. A correction factor for removal of radioactivity in blood samples (F3) was obtained from
where R is the total radioactivity injected and ti is the radioactivity removed in sample i that was corrected for decay.
To obtain protein-bound radioactivity in plasma samples, the non-TCA-precipitable radioactivity was subtracted from the radioactivity of the plasma sample. The whole body non-protein-bound radioactivity was estimated by multiplying the plasma value by a factor of 8.0 (21) .
Apparent plasma volumes were calculated from dilution of the '31I-AT or ['251I]fibrinogen between injection and the first blood sample (22) . Whole body radioactivity measurements of '3ll-AT were also corrected for radioactivity removed by blood sampling and a decay factor, as determined by counting a plastic rabbit phantom containing water and approximately the same amount of iodine-131 injected into the animals. No deadtime correction was required for the levels of '3'I-AT used in these studies. Corrected whole body (C*b) radioactivity was fitted to exponential equations of the form y(t) = Cwbe---, for t > 1 d.
Corrected plasma protein-radioactivity was fitted to equations of the form y(t) = Ce-al + * --+ Ce"e-", where n was either 2 or 3. This analysis was performed by curve "peeling" using the NIH PROPHET computing system (23) or a programmable calculator.
Results
The in vivo behavior of'31I-A T. Enzymobead protein iodination was used for label rabbit fibrinogen, a protein thats in vivo kinetic behavior has been well characterized (25) , as well as to iodinate AT. Fig. 1 Table I ing the time interval between its injection and the blood sample obtained 5-10 min later. The decreases in plasma '3'I-AT between injection and the first sample were reflected in decreases in the plasma radioactivities between the first and the subsequent plasma samples, as illustrated by the results shown in Fig. 1 . Early rapid removal of 11-AT was not accompanied by a concomitant rise in radioactive breakdown products, as illustrated by the lower curve (*A,) in Fig. 1 . Nor was the presence of a large initial increase in *A,-radioactivity, caused by early more rapid '311-AT catabolism, reflected in early more rapid whole body 13'I disappearance data. Thus, whole body radioactivity was fitted to a single exponential disappearance of the form Cwbe-a, in which Cwb was > 1.00. A test for the absence of denatured '3'I-AT was performed by study of the behavior of biologically screened material. The initial drop in plasma '3ll-AT was also observed under these conditions, as illustrated in Fig. 2 . Table I summarizes the values of the constants from Eq. 4 that best fit the plasma radioactivity data for six young rabbits injected with unscreened '3'I-AT and six each injected with screened 13'I-AT. The screened material was prepared by either the glucose oxidase-lactoperoxidase or iodine monochloride methods. Also shown in Table I 
Since the AT mass in the Aw compartment is unknown, the absolute rate cannot be obtained from Eq. 6. However, because the absolute catabolic rate is a constant, j3Ap = j3.5(Ap + Aw).
(7) Substituting j3, j3 .5, and the value of Ap into Eq. 7, the mass of AT in compartment Aw (Aw) can be calculated. Thus, a value of 11.7 mg or 4.7 mg/kg was obtained.
jT, the fractional rates of AT breakdown from the total body AT pool, were 0.225±0.016 and 0.244±0.013 day-' for screened and unscreened '311-AT, respectively (Table II) . The total body AT pool is distributed among three physiological compartments, Ap, Aw, and A,; thus, the absolute catabolic rate is related to jT as follows: ACR = jT(Ap + AW +A) (8) This equation can be combined with Eq. 5 to give j3Ap = jT(Ap + Aw + Aj). (9) Substituting the previously calculated values ofj3, Ap,, Aw, and jT, the mass of AT outside the vascular system, A, is 32. 
where *A is the labeled-AT in the respective compartment, and t > 2.5 d after '31I-AT injection (19) . During this time the '3'I-AT is in a steady state with respect to distribution between compartments. For each animal an average of Ap was obtained from plasma, whole body, and *A,-compartment radioactivity data up to t = 10 d. Because a significant fraction of the '"'I-AT was transferred from the circulation to the vascular-associated compartment before the first blood sample was taken, *Ap(t) and *A,(t) were corrected to account for this by dividing each fraction by C, + C2 + C3.
As discussed in the Appendix, at the time the first "steady state" has been achieved (t = SS,), the plasma and vascularassociated compartments can be considered as a single compartment. Only distribution of '3'I-AT to the extravascular space, giving rise to C2 and a2, and catabolism of '3'I-AT, giving rise to C, and a,, are then detected. For a two compartment system, when using an undenatured labeled-protein, C, + C2 is equal to the fraction of radioactivity of the labeled-protein present in the plasma at t = 0 (12). Thus, for '31I-AT, after equilibrium between plasma and vascular-asssociated compartments has been achieved, Cl + C2 = *Ap(SSI). (12) (13) Ap,, as calculated by Eq. 10, and C, + C2 were substituted into Eq. 13, and gave 0.178±0.056 for the average fraction of AT in the vascular-associated compartments, Aw (Table III) (14) (15) (16) Table I Compbrt-Calculation* Unscreened 
Finally,
A,= .00-AP-A .
The results obtained for the compartment sizes determined by this approach are essentially identical with those obtained using the mass-balance method (Table III) .
Discussion
The study of the in vivo kinetic behavior of radiolabeled AT results in a third generation ofin vivo kinetic analyses ofplasma proteins. The first generation studies were those conducted on albumin (e.g. references 11 and 24), a molecule thats in vivo distribution seems to be determined solely by hydrodynamic and concentration-dependent properties. Later plasma proteins studied were capable of undergoing activation from zymogen forms (e.g. references 25, 26, and 27). In the in vivo study of AT we are dealing with a molecule which, in addition to its hydrodynamic and concentration-dependent properties, and its ability to be converted from one form to another, also interacts with vascular endothelial cells (9) .
Here we show that the interaction ofplasma AT with another vascular site is detectable by analysis of data describing the in vivo kinetic behavior of rabbit '311-AT. Thus, a nonplasma vascular-AT pool or compartment is demonstrated by rapid initial decreases in plasma '311-AT, which is reflected in the high apparent 1311-AT plasma volume and the requirement of a fast third exponential to describe plasma '311-AT disappearance. In addition to our data, the early rapid disappearance of radioiodinated-AT has also been reported by others in studies of the disappearance of 1311-AT from rabbit plasma during the first 5 h after injection (28) . Our data were not the result ofdenaturation of AT during purification or iodination, which is demonstrated by the identical results with screened and unscreened '31I-AT, which are labeled by either the immobilized lactoperoxidaseglucose oxidase or by iodine monochloride methods. Furthermore, rapid removal of altered 1311-AT by catabolism is ruled out because of the absence of high levels of non-protein-bound iodine during the period corresponding to rapid '3I1-AT removal, and correspondingly, to CWb values of > 1.00. A final proof of the suitability of our '3'I-AT preparations to trace in vivo AT behavior comes from the jT/Ap data, which, shown by Eq. 15 (see also the Appendix), is equal to j3. Because JT and Ap, as obtained from by mass-balance, are dependent on data obtained in the steady state, any denatured material has been removed. Therefore, j3 calculated from jT/Ap is independent ofthe presence of any denatured 13'I-AT injected. As shown in Table II, Several types of compartmental kinetic models might describe the plasma and whole body radioactivities obtained after injection of '31I-AT in the rabbit. The simplest one would be the three-compartment model, which was proposed by Matthews (10) . As shown in Fig. 3 A, this consists of a central plasma compartment into which '3'I-AT is injected, and of two other compartments that exchange with the plasma independently. Calculation ofj3 was originally derived from this type of model (10) . Another reasonable compartmental model, among those possible, is shown in Fig. 3 B. In this series, or continuous model, AT is seen as moving from the plasma through the rapidly-equilibrating compartment to the extravascular space. This model considers that a pool of AT binding sites mediates the transfer of AT from plasma to interstitial fluids in a manner consistent with receptor-mediated formation of vesicles (29).
These could move across the endothelium as postulated by Ren- kin (30) .
Breakdown of AT in the models shown in Fig. 3 could be from any of the compartments. It has been suggested previously that AT breakdown occurs from the extravascular compartment, because a delay in the disappearance of total body radioactivity was observed in the dog and the human (31) . We have also observed this in the majority of our studies. To test this hypothesis for the rabbit, the system of differential equations de- algorithm. The fitting was performed using the PROPHET computing system (23) , and using the public procedure "DIF- were essentially identical to those obtained using Eq. 5 (see Table II ). Next, the solutions of the differential equations for each model were computer integrated, and the predicted values of the fractions of *AP, *A,, and *A, were obtained at the time of each blood sampling. At each of these times the sum of the predicted *Ap(t), *AW(t), and *AI(t) was added to the estimated total non-protein-bound radioactivities, which were determined from the non-TCA-precipitable radioactivity. This gave predicted whole body radioactivities for each catabolic-site variation ofmodels A or B. Ifbreakdown was from the same compartment, the predictions of whole body radioactivity were essentially identical for the two models. Fig. 4 data was more closely predicted by breakdown from plasma (e.g. rabbit R21, shown in Fig. 1 ), while others were closer to the prediction when breakdown was from the extravascular compartment (e.g. rabbit B5, shown in Fig. 2) . Generally, the data rested somewhere between the predictions obtained for breakdown from plasma and breakdown from extravascular space. These findings suggest that breakdown is not confined to a single compartment in rabbit, but that it occurs to variable degrees in both vascular and extravascular areas.
Mean sizes of the three compartments predicted by each kinetic model and those calculated directly from the radioactivity data are shown in Fig. 5 . The average differences for Aw were 0.056±0.030 for model A and 0.013±0.032 for model B, which, using a paired t test, were significantly different at the P < 0.0001 level. This suggests that model B, passage of AT from plasma to extravascular space via compartment Aw, best describes the in vivo behavior of rabbit AT.
In vivo kinetic analysis of radioiodinated AT in man (32, 33, 34) and dog (19, 35, 36) has been done previously by several investigators, but none have reported the presence ofadditional physiological AT compartments. The reason for the difference between our data and those of others may be partly species related. Preliminary studies on the behavior of human 13'I-AT indicate that a significantly smaller Aw pool is present in man. (A6)
The fractional catabolism of any plasma protein, P, can also be determined from the steady state portion of the *P-plasma or *P-whole body disappearance curves. Thus, after a steady state has been achieved with regard to distribution, the fraction of remaining labeled protein, F, at some later time, t, is described by F= e-1, (A7) in which "a" is a constant. For a constant time period during the steady state, the fraction of the remaining labeled protein that disappears is a constant, j, and is equal to 
where F1 is the fraction of labeled protein at t1 and F2 is the fraction at t2. For any 24-h period the fractional catabolic rate, calculated from Eq. A8, is the constant we have called jT. For example, the calculation of jT can be determined between t = 0 and t = I d, in which case jT = 1 -e-a.
(A9)
